Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
about
Ribavirin monotherapy for chronic hepatitis CRibavirin plus interferon versus interferon for chronic hepatitis CRibavirin Quantification in Combination Treatment of Chronic Hepatitis CThe science, economics, and effectiveness of combination therapy for hepatitis CHCV infection should be managed in specialist centresEfficacy of Interferon -2b and Ribavirin Against West Nile Virus In VitrosiRNAs: potential therapeutic agents against hepatitis C virusChronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP).Neopterin: Biomarker of cell-mediated immunity and potent usage as biomarker in silicosis and other occupational diseasesTGF-β/Smad signaling during hepatic fibro-carcinogenesis (review).Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C.Study of pruritus in chronic hepatitis C patients.Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.Inhibition of HCV 3a core gene through Silymarin and its fractions.In-vitro model systems to study Hepatitis C Virus.Lysosomotropic agents as HCV entry inhibitors.Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infectionTelaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infectionThe single dose pharmacokinetics of ribavirin in subjects with chronic liver diseaseRibavirin Does Not Impair the Suppressive Activity of Foxp3(+)CD4(+)CD25(+) Regulatory T Cells.Clinical presentation and management of suspected ribavirin toxicosis in a dogRibavirin in the treatment of chronic hepatitis C.Treatment of chronic hepatitis C in hemodialysis patients.Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model.Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase.The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.Biotherapeutic bioanalysis: a multi-indication case study review.Targeting the "cytokine storm" for therapeutic benefit.Hepatitis C infection and chronic renal diseases.Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.Down-regulation of IRES containing 5'UTR of HCV genotype 3a using siRNAs.Inhibition of Borna disease virus replication by ribavirin.Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases.Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed.Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, versus its achievable concentrations in the human respiratory tract and comparison to ribavirin.Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients.Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a.
P2860
Q24240057-A9E4F548-556C-4906-9F9F-6A26FEFEDB8CQ24240879-070DA4BF-9173-44E7-93D8-C3823CF004F1Q27473304-371D4109-7D8F-4CDD-AD16-20B662C1DFDCQ27477845-C28FAA22-C3C2-4D4C-A482-30A6ED01F660Q27477960-1E1B7EAA-408E-42C8-AEBB-34A3037E1982Q27489383-B97E2599-0462-4565-927E-371331900C9DQ27694682-6BAC517D-63E8-4FFC-ACE9-595F37A2C946Q30580854-86D8F480-59D9-4EC1-8E68-2E02FBB7A8CDQ33551537-FA93110D-1FAD-4EA6-9334-8C5ECDBDF77FQ34120419-5857066E-D0BF-4C31-9156-19A2D17D9402Q34359514-330A4706-C644-40C3-9626-E14827736E97Q34750602-9AB22122-7D30-4722-A442-C29E19F065D6Q34799396-5184AB2F-8FB2-4372-9B94-B7044EC320D7Q34809056-4B625740-1C13-4B4E-A3A5-98E0AB33B308Q34870944-8366216D-094D-4F3D-B98B-99EEDA5A0E29Q34957340-B59F7C5C-7B70-4012-BEEF-334F49C98A45Q35169059-CBC74362-DFC5-475A-98F9-EB92E91F7C91Q35607785-29714AAC-6BEC-4756-81C9-9F63E46AD082Q35825285-C79BF66D-F216-4FC4-80AA-C91203FA77DDQ36055167-16994AE6-5FB2-4493-B008-22D3153714FEQ36714921-41816F60-765C-4528-9462-C6ED11813916Q36787397-7ECBEA87-6885-47CC-8EF4-868BFC2971ACQ37195248-DBB5568C-EF0D-4AE2-B26D-C8E8FF3B21DDQ37313163-7F525C6A-0B0D-428A-85D0-2C54215EE9C8Q37583537-58FAEC08-69B6-492E-8395-97CD89BD9620Q37624964-7245F51D-DA1D-4B78-BC35-0548E229B60EQ37634196-7E4E3393-5796-42C9-B810-54FC653331F2Q37854629-7A6F01CF-3D09-410D-ABAF-C8681D6672A2Q38071254-5922FF69-B6B2-455D-BA8E-DE1B8DEEF9FBQ38552198-D98795A1-9E9E-4805-843B-2E62D09FBE35Q39471947-D6821CA6-3BF4-4DCD-A8DA-30860FDB1E1FQ39543313-36FA90DB-4323-4238-AAA0-91CBB7A988E5Q39551221-ED6B0A93-7B13-4434-A856-445067F1E325Q40280603-A757A498-CC01-435B-A2EB-7BC6EA3F204EQ40514804-66335F59-44FA-4201-AF49-4506D08FFC84Q40761586-FAC39214-6B52-4287-B2B1-043A03324DCAQ41144825-D75FA988-3254-4167-BF11-CB88943545CCQ41921750-269AD582-5246-4552-AA4B-14AD15B91516Q42205181-2836C5A4-E4DE-442A-BBD4-694F9362DA22Q42979765-E54F3828-5156-480E-B0E4-EF780376332E
P2860
Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Ribavirin and interferon alfa- ...... pharmacodynamic interactions.
@ast
Ribavirin and interferon alfa- ...... pharmacodynamic interactions.
@en
type
label
Ribavirin and interferon alfa- ...... pharmacodynamic interactions.
@ast
Ribavirin and interferon alfa- ...... pharmacodynamic interactions.
@en
prefLabel
Ribavirin and interferon alfa- ...... pharmacodynamic interactions.
@ast
Ribavirin and interferon alfa- ...... pharmacodynamic interactions.
@en
P2093
P2860
P1476
Ribavirin and interferon alfa- ...... pharmacodynamic interactions.
@en
P2093
B Flannery
G M Dusheiko
I Murray-Lyon
L Grellier
P2860
P304
P356
10.1046/J.1365-2125.1998.00836.X
P407
P50
P577
1998-12-01T00:00:00Z